Novel Pramipexole-Rasagiline Combo Promising for Early Parkinson Disease

A phase 3 study evaluating a novel fixed-dose combination of extended release pramipexole and rasagiline (P2B001) in adults with early Parkinson disease met its primary and key secondary endpoints.

Related Keywords

Sheila Oren ,Drug Administration ,Unified Parkinson Disease Rating Scale ,Epworth Sleepiness Scale ,Chief Executive Officer ,Pharma Two ,New Drug Application ,